Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cross tolerance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    53 result(s) found for: Cross tolerance. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-005744-24 Sponsor Protocol Number: DM-99-07 Start Date*: 2008-02-11
    Sponsor Name:DiaMedica Inc.
    Full Title: A phase IIa, placebo controlled, randomized, cross-over study to evaluate the effects of DM-99 on a meal tolerance test in subjects with type 2 diabetes mellitus
    Medical condition: Cukrzyca
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004862-89 Sponsor Protocol Number: mirtazapine1 Start Date*: 2015-02-16
    Sponsor Name:KULeuven
    Full Title: The effect of mirtazapine (REMERGON®) on gastric motility and satiation in healthy subjects
    Medical condition: Functional Dyspepsia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001869-32 Sponsor Protocol Number: 24042019 Start Date*: 2020-01-29
    Sponsor Name:Radboudumc
    Full Title: Nano-MRI to visualize pancreatic inflammation in individuals with recent-onset type 1 diabetes
    Medical condition: Type 1 Diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005371-34 Sponsor Protocol Number: 2 39 00240 133 Start Date*: 2008-03-18
    Sponsor Name:BEAUFOUR IPSEN PHARMA
    Full Title: EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIA A 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study.
    Medical condition: Out patient suffering from friedreich ataxia aged from 12 to 20 years
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005655-42 Sponsor Protocol Number: AmilorideOGTT1 Start Date*: 2008-01-17
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
    Full Title: STUDY TITLE: - Early Metabolic Changes with Thiazide or Beta blocker Therapy for Essential Hypertension – open label extension phase with the potassium sparing diuretic- Amiloride.
    Medical condition: Essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010422-20 Sponsor Protocol Number: CMC-P010 Start Date*: 2010-01-18
    Sponsor Name:CMC Contrast AB
    Full Title: Evaluation of the imaging quality of CMC-001(manganese chloride tetrahydrate) in liver Magnetic Resonance Imaging (MRI) in healthy volunteers. A double-blind, randomized cross-over, dose-response s...
    Medical condition: Liver Magnetic Resonance Imaging (MRI) in healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001270-41 Sponsor Protocol Number: CPRC2015/HSNORDOB-AUCHET/YB Start Date*: 2019-07-17
    Sponsor Name:CHRU NANCY
    Full Title: Norepinephrine alone vs Norepinephrine and Dobutamine in cardiogenic shock : a randomised, opened, cross-over study. Heart SHOCK-NORDOB Study
    Medical condition: Cardiogenic Shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000700-84 Sponsor Protocol Number: pasireotide01 Start Date*: 2008-07-28
    Sponsor Name:UZ Leuven
    Full Title: A single center trial with a randomized, double-blind, placebo-controlled phase to assess safety and efficacy of sc pasireotide in patients with dumping syndrome, followed by an open label phase on...
    Medical condition: dumping syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013810 Dumping syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000828-28 Sponsor Protocol Number: 52642 Start Date*: 2016-07-26
    Sponsor Name:UMC Utrecht
    Full Title: Titlle: Subcutaneous immunoglobulins with rHuPH20 in multifocal motor neuropathy (MMN) It is an interventional cross-over study where the use of the combination of subcutaneous immunoglobulins ...
    Medical condition: Non-inferiority and safety/tolerance of Hyqvia compared to IVIg in 20 MMN patients with at least one conduction block on EMG and stable on IVIg.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004837-41 Sponsor Protocol Number: DM-83-07 Start Date*: 2007-12-11
    Sponsor Name:DiaMedica Inc.
    Full Title: A phase IIa, placebo controlled, randomized, cross-over study to evaluate the effects of DM-83 on a meal tolerance test in subjects with type 2 diabetes mellitus
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012614 Diabetes mellitus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001250-91 Sponsor Protocol Number: GV-002.001 Start Date*: 2005-10-04
    Sponsor Name:GenVec, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of BIOBYPASS® (ADGVVEGF121.10NH) Delivered by NOGA-Guided/MYOSTAR Catheter in "No Option" Patients with Cla...
    Medical condition: Moderate to severe angina pectoris due to advanced coronary artery disease (CAD).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) AT (Completed) DE (Completed) GB (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005656-26 Sponsor Protocol Number: 51748.094.15 Start Date*: 2015-10-14
    Sponsor Name:Westfriesgasthuis
    Full Title: Amitriptyline 10% and ketamine 10% cream in neuropathic pain: A randomised, double-blind, placebo-controlled cross-over pilot study with a three months open follow-up
    Medical condition: Patients with peripheral neuropathic pain or scar pain
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10049002 Scar pain PT
    17.1 100000004852 10029181 Nerve pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-005282-37 Sponsor Protocol Number: IDT.LM.LEV.22004-LEMDE Start Date*: 2005-05-24
    Sponsor Name:QUIMICA FARMACEUTICA BAYER, S.A.
    Full Title: Double-blind, cross-over, placebo-controlled pilot study to characterize the profile of those patients with traumatic spinal cord injury diagnosed by electrophysiological, urodynamic and clinical (...
    Medical condition: Erectile dysfunction (ED)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000580-78 Sponsor Protocol Number: EMPAtia Start Date*: 2022-02-02
    Sponsor Name:The Children’s Memorial Health Institute
    Full Title: "The assessment of effectiveness and safeness of utilizing empagliflozin in the treatment of neutropenia of patients suffering from glycogenolysis type Ib"
    Medical condition: neutropenia and / or abnormal neutrophil function in glycogenosis I b
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023090-19 Sponsor Protocol Number: SMR 2375 Start Date*: 2011-03-29
    Sponsor Name:AlgiPharma AS
    Full Title: A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subje...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000583-34 Sponsor Protocol Number: AGLU03707_MSC12817 Start Date*: 2015-04-15
    Sponsor Name:Genzyme Corporation Inc
    Full Title: An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients with Pompe Disease Who Have Previously Received Myozyme
    Medical condition: Pompe disease (acid alpha-glucosidase deficiency)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10036143 Pompe's disease LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-018597-20 Sponsor Protocol Number: CNVA237A2310 Start Date*: 2010-08-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo- controlled, two-period cross-over study to assess the effect of 50µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001244-38 Sponsor Protocol Number: 14SM1971 Start Date*: 2014-07-16
    Sponsor Name:Imperial College London
    Full Title: Preventing Recurrent Gestational Diabetes Mellitus with Early Metformin Intervention
    Medical condition: Gestational diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004868 10018210 Gestational diabetes mellitus LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-000730-19 Sponsor Protocol Number: DC2019ROCKIES1 Start Date*: 2020-03-05
    Sponsor Name:Amsterdam Univeristy Medical Center - Vu Univeristy Medical Center
    Full Title: A phase 4, monocenter, prospective, randomized, placebo-controlled, double-blind, cross-over mechanistic intervention trial to assess effect of 4-week Ertugliflozin (SGLT-2 inhibitor) therapy on re...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016921-32 Sponsor Protocol Number: HSJD-OB-TRP Start Date*: Information not available in EudraCT
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: A phase II, randomized, double-blind, placebo-controlled, in parallel groups clinical trial to assess the safety and efficacy of dietary supplementation with tryptophan to achieve weight loss, and ...
    Medical condition: obesity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:58:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA